Akari Therapeutics Plc · NASDAQ:AKTX
Akari Therapeutics — Investor Presentation (April 2025)
29 slides from Akari Therapeutics's investor presentation, April 2025
Slide 1: Next-Generation Precision Bi-Functional Antibody Drug Conjugates
Corporate Presentation Next-Generation Precision Bi-Functional April 2025 Antibody Drug Conjugates NASDAQ: AKTX akaritx.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes expressed or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), about the Akari Therapeutics, Plc
Slide 3: We Are Akari Therapeutics
WE ARE AKARI THERAPEUTICS Akari Therapeutics is an innovative targeted oncology company built on next-generation ADCs and a novel discovery engine 3
Slide 4: Why Akari
Why Akari Lead Candidate AKTX-101 (TROP2 PH1 ADC) Innovative Precision Antibody Significant advantages over current TROP2 ADCs Drug Conjugates (ADCs) for the observed in multiple preclinical models: Treatment of Cancer - Superior activity - Prolonged survival Discovery platform allows for - Less res
Slide 5: ADCs Have Revolutionized Cancer Therapy, but Have Some Shortcomings
2023 Sales from Approved ADCs ADCs Have Revolutionized Product Toxin Class 2023 Sales Cancer Therapy, but DNA Damaging Agent DNA Damaging Agent $1.0B $2.7B Have Some Shortcomings Solid Tumors Microtubule Inhibitor <$100M Microtubule Inhibitor $1.75B All Currently Approved ADCs Utilize One of Only Mi
Slide 6: Significant Big Pharma Interest and Deal Flow in Early-Stage ADCs
Significant Big Pharma Interest and Deal Flow in Early-Stage ADCs Licensee Licensor Phase Asset Target Date Deal Type Upfront Payment Total Deal Highlights Entire 3 Preclinical Acquired 3/2025 Acquisition $400M $400M upfront + $740M in potential milestones Company Preclinical 1 ADC Undisclosed 1/202
Slide 7: Bi-Functional ADC Designed to Kill Cancer Cells and Activate the Immune System
Bi-Functional ADC Designed to Kill Cancer Cells and Activate the Immune System Highly Selective Cancer Cell Death Combined With Enhanced Immune System Engagement for Effective Tumor Eradication Payload Antibody Linker Differentiated Novel PH1 Payload Targeting Clinically Connects Anti-Tumor Payload
Slide 8: Next-Generation Precision ADC Pipeline
Next-Generation Precision ADC Pipeline Program Indication Discovery Preclinical Clinical Highlights • Novel Payload: PH1 AKTX-101 • Advancing IND-enabling (TROP2 PH1 ADC) Solid Tumors preclinical studies ADC with Novel Payload • Pursue licensing / strategic partnership • Novel Payload: PH5 AKTX-102
Slide 9: Akari Platform Technology Can Fuel a Pipeline
Akari Platform Technology Can Fuel a Pipeline Ability to Precisely Tune Assets for Purpose Allows for Multiple Program Development for Additional Licensing Partnerships Application Targeting Antibody Proprietary Linkers Anti-Cancer Payload Lung Cancer CD20 Lys-L92 Colorectal Cancer Nectin-4 Lys-L91
Slide 10: Novel PH1 Payload: Superior Preclinical Activity Across Tumor Types
Novel PH1 Payload: Superior Preclinical Activity With Potent Effect Across Various Tumors Types and Targets Using Platform Technology In Vitro Studies Performed at Lower PH1 Drug Dose (Lower DAR) Gastric Trop2High Bladder Trop2Heterogenous Pancreatic Trop2High 100 100 100 Trop2 PH1 (DAR4) Trop2 PH1
Slide 11: Lung Cancer Market Is Ripe for Disruption with a Best-In-Class ADC
Lung Cancer Market Is Ripe for Disruption with a Demonstrate Greater Activity Preclinically at Lower DAR Ratios as Compared to Best-In-Class ADC Currently Available TROP2 ADC’s AKTX-101 has the potential for a first mover advantage in 2L Non-Small Cell Lung Cancer (NSCLC) A Total $2 Billion Market O
Slide 12: AKTX-101: Novel Payload is a Spliceosome Inhibitor
AKTX-101: Novel Payload is a Spliceosome Inhibitor With Multiple Anti-Tumor Mechanisms Novel Anti-Cancer Payload That Disrupts RNA Splicing Within Cancer Cells, Inducing Tumor-Specific Cell Death While Generating Immunostimulatory Effects and Minimizing Off-Target Toxicity Potential to Overcome Shor
Slide 13: AKTX-101: Direct Tumor Cell Cytotoxicity and Generation of Neoantigens
AKTX-101: Direct Tumor Cell Cytotoxicity and Generation of Neoantigens Bi-Functional Payload Targeting the Spliceosome Bi-functional results of PH1 targeted splicing 1 PH1 ADC binds MHC Neoantigen to the target PH1 receptor. TUMOR CELL MEMBRANE TROP2 Neoantigen formation can stimulate the immune res
Slide 14: Immune Response to Payload-Induced Neoantigens Extends Beyond ADC Target
AKTX-101: PH1 ADC Immune Response to Payload-Induced Neoantigens Extends Target receptor Beyond ADC Target Receptor (Her2 or Trop2) Cancer neoepitope Myeloid cell Activation T cell Activation B cell Payload induced neoepitope TCR T cells recognize neoantigens and become B cells recognize neoantigens
Slide 15: PH1 Payload Treated Mice Retained Immune Memory and Rejected Rechallenge
PH1 Payload Treated Mice Retained Immune Memory and Rejected Rechallenge with Tumor Cells Potent Synergy With Checkpoint Inhibitor PH1 Induced Tumor-Specific Has Potential to Cure Colorectal Tumors Immune Memory ADC Treatment and Survival Curves Rechallenge MC38-hHer2 ADC Doses MC38-hHer2 B16-F10 Tu
Slide 16: AKTX-101: Novel Payload is a Spliceosome Inhibitor
AKTX-101: Novel Payload is a Spliceosome Inhibitor With Multiple Anti-Tumor Mechanisms Novel Anti-Cancer Payload That Disrupts RNA Splicing Within Cancer Cells, Inducing Tumor-Specific Cell Death While Generating Immunostimulatory Effects and Minimizing Off-Target Toxicity Potential to Overcome Shor
Slide 17: AKTX-101: Demonstrated Reduced Off-Target Toxicity in Normal Human Fibroblasts
AKTX-101: Demonstrated Reduced Normal Human Fibroblasts Off-Target Toxicity in TROP2none Preclinical Study Limited effect on Normal Human Fibroblasts, an example of off-target toxicity of Trodelvy® Proprietary Linker Only Releases PH1 Payload Upon Cell Internalization – No Leakage Suggests Potential
Slide 18: Safety Profile has Been Well Established in NHP Model
Safety Profile has Been Well Established in NHP Model No Toxicities Related to Neutropenia, Diarrhea, Mucosal Inflammation or Interstitial Lung Disease Tolerated in NHP at doses well above efficacious dose • DAR2 ADC tolerated at 6mpk Q3W X3 • DAR4 ADC tolerated at 6mpk Q3W X3 Mitigatable side-effec
Slide 19: AKTX-101: Novel Payload is a Spliceosome Inhibitor
AKTX-101: Novel Payload is a Spliceosome Inhibitor With Multiple Anti-Tumor Mechanisms Novel Anti-Cancer Payload That Disrupts RNA Splicing Within Cancer Cells, Inducing Tumor-Specific Cell Death While Generating Immunostimulatory Effects and Minimizing Off-Target Toxicity Potential to Overcome Shor
Slide 20: Unique Payload Offers Potential to Overcome Resistance Mechanisms
Unique Payload Offers Potential to Overcome Resistance Mechanisms Seen By Current ADCs PH1 payload is designed to evade MDR transporter efflux pumps and is unaffected by mutations in >90% of ADCs in clinical and tubulin or DNA damage pathways that confer preclinical development still have resistance
Slide 21: AKTX-101: Shown to Avoid Development of Resistance in Preclinical Study
120 100 AKTX-101: Shown to Avoid % Live Cells 80 Development of Resistance in 60 MES-SA MES-SA/MX2 40 PH1 MES-SA/MX2 + Preclinical Study 20 Elacridar 0 0.0001 0.01 1 100 10000 Concentration [nM] PH1 potency unaffected by overexpression of Method: Normal MES-SA cells & MES-SA cells selected for multi
Slide 22: AKTX-101: Novel Payload is a Spliceosome Inhibitor
AKTX-101: Novel Payload is a Spliceosome Inhibitor With Multiple Anti-Tumor Mechanisms Novel Anti-Cancer Payload That Disrupts RNA Splicing Within Cancer Cells, Inducing Tumor-Specific Cell Death While Generating Immunostimulatory Effects and Minimizing Off-Target Toxicity Potential to Overcome Shor
Slide 23: AKTX-101 Demonstrates Strong In Vivo Activity as a Single Agent and With Checkpoint Inhibitor
AKTX-101 Demonstrates Strong In Vivo Activity as a Single Agent and With a Checkpoint Inhibitor, Driving Anti-Tumor Activity and Enhancing Overall Survival With Standard of Care I/O Mouse Bladder Syngeneic Cancer Tumor Model (Urothelial) Expressing Human TROP2 Protein Superior Anti-Tumor Efficacy In
Slide 24: Proven Management Team
Proven Management Team Abizer Gaslightwala, Torsten Hombeck, PhD Miles Nunn, D. Phil Satyajit Mitra, PhD MS, MBA Chief Financial Officer Chief Scientific Officer Executive Director, President, Head of Oncology Chief Executive Officer Seasoned executive with over Accomplished scientist and drug Scien
Slide 25: Highly Experienced, Involved, Knowledgeable Board
Highly Experienced, Involved, Knowledgeable Board to Help Steer Strategy and Execution Hoyoung Huh, MD, PhD Abizer Gaslightwala Samir R. Patel, MD Chairman President, Chief Executive Officer Director Founder of Peak Bio Inc. and has held 25 years in the development and commercialization of novel Fou
Slide 26: Upcoming Expected Value Driving Milestones
Upcoming Expected Value Driving Milestones Building a Next-Generation Legacy Pipeline Precision Bi-Functional ADC Platform Assets Ongoing and Near-Term Ongoing • Present anticipated PH1 Payload Preclinical Data at Scientific Conference BD Efforts to Secure • Complete additional IND-enabling preclini
Slide 27: Assets Beyond ADC Platform
Assets Beyond ADC Platform Opportunity for Non-Dilutive Capital Through Ongoing BD Activities to Secure Development Partner for Inactive Programs Global Market Program Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Opportunity PAS-Nomacopan Long-Acting Complement C5 & Geographic Atrophy $2
Slide 28: Why Now
Why Now Next-Generation Precision Antibody Drug Conjugates (ADC) Candidates for the Treatment of Cancer Innovative Bi-Functional ADC Platform with New Payloads and Alternative Mechanisms Customizable Targets by Tumor, Novel Payloads and Unique Linkers to Generate a Pipeline of Superior ADCs for Out-
Slide 29: Investor Relations
Investor Relations Next-Generation Precision Bi-Functional JTC Team aktx@jtcir.com Antibody Drug Conjugates (908) 824-0775
Akari Therapeutics — Investor Presentation (April 2025) on 6ix